Login / Signup

Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review.

Ilse Andrea Moreno-ArquietaJesus A Cardenas-de la GarzaJorge Antonio Esquivel-ValerioJanett Carmen Luzmila Riega-TorresAdrian B Cuellar-BarbozaMaira Elizabeth Herz RuelasJorge Ocampo CandianiDionicio Ángel Galarza-Delgado
Published in: The Journal of dermatological treatment (2021)
Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords 'eosinophilic fasciitis', 'Shulman syndrome', 'mycophenolic acid', or 'mofetil mycophenolate', and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects.
Keyphrases
  • newly diagnosed
  • case report
  • combination therapy
  • systematic review
  • clinical trial
  • stem cells
  • open label
  • bone marrow
  • mesenchymal stem cells
  • robot assisted
  • soft tissue
  • patient reported
  • double blind